For almost three decades, patient non-compliance with therapeutic regimens
has been recognized as a challenge to the successful delivery of healthcare. For
the pharmaceutical executive, estimating and improving patient compliance
continues to be a major challenge in forecasting and achieving expected
revenues. Scientists, physicians, legislators and the pharmaceutical industry
realize that successful delivery of healthcare is dependent upon in part the
willingness and motivation of patients to participate in the prescribed
treatment regimens. Well-designed Patient Education and Disease Management
Programs have a positive influence on patient adherence; changes in
drug-delivery that can reduce the complexity involved with taking a medication,
reduce the side-effects, or make taking it more appealing can have a strongly
positive effect. As a result, there is a heightened emphasis on the development
and implementation of effective intervention programs, and on drug-delivery
characteristics that might improve patient compliance.
The growing consumer emphasis on quality of life and improvement in long-term
health, along with the availability of new treatments, make accurate prediction
of treatment utilization especially difficult. Patient compliance ranges widely
between sub-populations of patients with a specific condition. The designers of
patient education programs and drug delivery need to address the patients at
highest risk for non-compliance, and have a clear understanding of the reasons
for non-compliance in those patient sub-populations.
There are special challenges involved with inspiring patients to take
medications as prescribed.
The five most common forms of noncompliance are:
- not having the prescription filled,
- taking the incorrect dose,
- taking the medication at the wrong time,
- forgetting to take one or more doses,
- stopping the medication to soon1.
Understanding the reasons for these forms of non-compliance is of key
importance to the successful development of potential program and product
improvements.
This publication will provide the pharmaceutical marketer greater insights on
the topic of patient compliance, with special in-depth coverage of a condition
most affected by patient compliance.
EP Publications are designed to identify opportunities and to enhance
strategic decisions. Each EP Publication capitalizes on the authors'
expertise, ranging from line management to technology and market assessment.
With the Psoriasis Compliance Report, you receive valuable, expert opinions,
actionable insights, and new information. In addition, EP Publications is
soliciting suggestions for supplemental topics to
be reported.
View Cart
